Normal and Pathological Values of Postvoiding Residual Volume in Early Postpartum Period and Their Predisposing Factors (PAREZ)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03958279 |
Recruitment Status :
Recruiting
First Posted : May 22, 2019
Last Update Posted : May 22, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Urinary Retention | Diagnostic Test: Ultrasound measurement of residual volume in the urinary bladder Diagnostic Test: Questionnaire |
Pregnancy itself and vaginal delivery are well known risk factors for pelvic floor dysfunction. The rise in progesterone related to pregnancy has an inhibitory effect on bladder smooth muscle - decreased smooth muscle tonus in lower urinary tract. Weight and pressure of pregnant uterus and loosening of some of the pelvic ligaments changes the statics of pelvic floor. In addition, delivery itself influence lower urinary tract; an overdistension of urinary bladder can occur easily, also as oedema of urethra or urethral hinge apparatus injury during "crowning" of the fetal head.
All of these factors can affect consecutive function of lower urinary tract right after delivery. It is known that in 1,5% of women giving birth, symptomatic urinary retention develop in early postpartum period, with necessity of insertion of an indwelling catheter. Discussed risk factors are: epidural analgesia, instrumental delivery and primiparity. The investigators can assume that every woman in early postpartum period has (to some extend) even in normal circumstances postvoiding residual volume. There is few evidence in a literature about this postpartum residual volume and its predisposing factors.
Postvoiding residual volume can be risk factor for postpartum urinary infection, which forms second largest part in infectious morbidity of women. By determination of risk factors (for increased post voiding residual volume) the investigators could narrow the group of women which necessitate increased attention in postpartal monitoring.
Study Type : | Observational |
Estimated Enrollment : | 1200 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Normal and Pathological Values of Postvoiding Residual Volume in Early Postpartum Period and Their Predisposing Factors (PAREZ - Partus - Residual Urine) |
Actual Study Start Date : | February 1, 2018 |
Estimated Primary Completion Date : | February 28, 2020 |
Estimated Study Completion Date : | February 28, 2020 |

Group/Cohort | Intervention/treatment |
---|---|
primipara giving birth
The investigators involve every primipara giving birth in a period of two years. Exclusion criteria:
|
Diagnostic Test: Ultrasound measurement of residual volume in the urinary bladder
Aim of this study is to asses post voiding residual volume by ultrasound scan 3th day after delivery with consecutive scan after 6 weeks, and determination of data dispersion among the population of primiparas. Diagnostic Test: Questionnaire Simple questionaire concerning voiding problems, infectious complications, medicaments and breastfeeding during puerperium period (6weeks) |
- Change in postvoiding residual volume [ Time Frame: 6 weeks ]Volume of remaining urine in the urinary bladder after micturition - assessed by ultrasound, third day after delivery, and 6 weeks after delivery

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | primipara giving birth |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- The investigators involve every primipara giving birth at 2nd Department of Obstetrics and Gynecology, University Hospital Bratislava and Comenius University, Bratislava, Slovak Republic in a period of two years
Exclusion Criteria:
- Unwilling to participate
- Minors (under 18 years old)
- Foetus mortus or perinatal death of the newborn
- Admission of the newborn to the ICU
- Unfamiliar with slovak language
- Multiple pregnancy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03958279
Contact: Pavel Doležal, MD | +4219010579496 | palodolezal@hotmail.com |
Slovakia | |
2nd Department of Obstetrics and Gynecology, University Hospital Bratislava and Comenius University, Bratislava, Slovak Republic | Recruiting |
Bratislava, Slovensko, Slovakia, 83232 | |
Contact: Pavol Doležal, MD +421910579496 palodolezal@hotmail.com |
Study Chair: | Jozef Záhumenský, MD, PhD. | Comenius University, Faculty of Medicine, 2nd Department of Obstetrics and Gynecology |
Responsible Party: | Comenius University |
ClinicalTrials.gov Identifier: | NCT03958279 History of Changes |
Other Study ID Numbers: |
EC/002/2018/UNBRuzinov |
First Posted: | May 22, 2019 Key Record Dates |
Last Update Posted: | May 22, 2019 |
Last Verified: | May 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
postvoiding residual volume early postpartum period |
Urinary Retention Urination Disorders Urologic Diseases |